Fungal Infections and New Biologic Therapies

被引：0
作者：
Snigdha Vallabhaneni
Tom M. Chiller
机构：
[1] National Center for Emerging and Zoonotic Diseases,Mycotic Diseases Branch, Division of Food, Water, and Environmental Diseases
[2] The Centers for Disease Control and Prevention,undefined
来源：
Current Rheumatology Reports | 2016年 / 18卷
关键词：
Biologics; TNF-alpha inhibitors; Anakinra; Abatacept; Rituximab; Ustekinumab; Tocilizumab; Tofacitinib; Vedolizumab; Secukinumab; Ixekizumab; Fungal infections; Histoplasmosis; Candidiasis; Cryptococcosis; Coccidioidomycosis; Aspergillosis; Incidence; Risk; Prevention;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The development of biologic therapies targeting proinflammatory mediators has led to significant advances in the treatment of immune-mediated inflammatory diseases (IMIDs). Blocking undesired inflammatory effects also has the potential to disrupt the body’s immune response and increase the risk for infections, including fungal infections. This review summarizes the published data on the frequency and risk for fungal infections among patients treated with biologics, with a focus on the newer therapies approved for use with IMIDs in the last 10 years. The use of biologics is associated with a small but important risk of fungal infections. Pneumocystis jirovecii pneumonia, histoplasmosis, and candidiasis are some of the most common fungal infections associated with biologics. Providers should be vigilant for fungal infection among patients taking biologics, be aware that biologic agents may alter the typical presentation of fungal infections, and take timely steps to diagnose and treat fungal infection to reduce resultant morbidity and mortality.
引用
收藏
相关论文
共 174 条
[1]  
Novosad SA(2014)Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae Clin Infect Dis 58 1587-98
[2]  
Winthrop KL(2002)Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study Arthritis Rheum 46 2287-93
[3]  
Doran MF(2011)The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses Arthritis Res Ther 13 R139-57
[4]  
Crowson CS(2014)Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis Clin Infect Dis 58 1649-8
[5]  
Pond GR(2014)Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study Ann Rheum Dis 73 1942-85
[6]  
Dixon WG(2006)Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2275-76
[7]  
Suissa S(2013)Opportunistic Infections With Anti-Tumor Necrosis Factor-[alpha] Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials Am J Gastroenterol 108 1268-31
[8]  
Hudson M(2011)Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly Rheumatology (Oxford) 50 124-23
[9]  
Kourbeti IS(2011)Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry Ann Rheum Dis 70 616-94
[10]  
Ziakas PD(2008)Fungal infections complicating tumor necrosis factor alpha blockade therapy Mayo Clin Proc 83 181-70
12345678910